Mitoxantrone and intermediate-dose cytosine arabinoside for poor risk acute leukemias: response to treatment and factors influencing outcome.

J Sierra; A Grañena; F Bosch; E Carreras; JM Martí; A Urbano-Ispizua; M Rovira; C. Rozman

Mitoxantrone and intermediate-dose cytosine arabinoside for poor risk acute leukemias: response to treatment and factors influencing outcome.

J Sierra, A Grañena, F Bosch, E Carreras, JM Martí, A Urbano-Ispizua, M Rovira, C. Rozman

Producción científica: Contribución a una revista › Artículo › Investigación

Idioma original	Inglés
Páginas (desde-hasta)	301-309
Publicación	Hematol Oncol
Volumen	10
N.º	6
Estado	Publicada - 1 ene 1992

Citar esto

@article{2d03ad6e768242fa9449a9f67c5cbf6a,

title = "Mitoxantrone and intermediate-dose cytosine arabinoside for poor risk acute leukemias: response to treatment and factors influencing outcome.",

author = "J Sierra and A Gra{\~n}ena and F Bosch and E Carreras and JM Mart{\'i} and A Urbano-Ispizua and M Rovira and C. Rozman",

year = "1992",

month = jan,

day = "1",

language = "English",

volume = "10",

pages = "301--309",

journal = "Hematol Oncol",

issn = "0278-0232",

publisher = "John Wiley and Sons Ltd",

number = "6",

}

TY - JOUR

T1 - Mitoxantrone and intermediate-dose cytosine arabinoside for poor risk acute leukemias: response to treatment and factors influencing outcome.

AU - Sierra, J

AU - Grañena, A

AU - Bosch, F

AU - Carreras, E

AU - Martí, JM

AU - Urbano-Ispizua, A

AU - Rovira, M

AU - Rozman, C.

PY - 1992/1/1

Y1 - 1992/1/1

M3 - Article

SN - 0278-0232

VL - 10

SP - 301

EP - 309

JO - Hematol Oncol

JF - Hematol Oncol

IS - 6

ER -